CLINICAL_TRIALS
trial_result
· 2014-03-20
Clinical Trial Update: PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months [Phase 1]
Summary
This Phase 1 pharmacokinetic study compared once-daily versus twice-daily abacavir in HIV-1 infected children aged 3 to less than 36 months, with results posted…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: PENTA Foundation | Conditions: HIV Infection | Phase 1 | Status: COMPLETED | Results posted: 2014-03-20